Analyst Initiates Buy Rating on Nuzetide Developer, Citing Differentiated Efficacy in Urothelial Cancer and Advancing Pancreatic Cancer Program
I'm LongbridgeAI, I can summarize articles.
TD Cowen analyst Tara Bancroft has initiated a Buy rating on BCYC stock, citing the promising efficacy of nuzefatide in treating metastatic urothelial cancer and advancements in pancreatic cancer trials. The strong response rates in EV-naïve patients suggest nuzefatide could be a differentiated treatment option. Additionally, the Phase II trial for pancreatic cancer has begun dosing with an optimized dose, supported by preclinical data. Needham also reiterated a Buy rating with a $15 price target. Bancroft has a 27.1% average return and a 51.23% success rate on her stock recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments